YemenTuberculosis profile
Population  2014 26 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.1 (0.74–1.6) 4.4 (2.8–6.2)
Mortality (HIV+TB only) 0.025 (0.019–0.031) 0.1 (0.07–0.12)
Prevalence  (includes HIV+TB) 16 (7.2–29) 63 (27–112)
Incidence  (includes HIV+TB) 13 (11–14) 48 (42–54)
Incidence (HIV+TB only) 0.08 (0.062–0.1) 0.31 (0.24–0.38)
         
Case detection, all forms (%) 77 (68–88)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 1.7 (0.5–3) 15 (8.1–22)
MDR-TB cases among notified pulmonary
TB cases
100 (30–180) 38 (21–56)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 2 912   191
Pulmonary, clinically diagnosed 3 135   0
Extrapulmonary 3 390   0
       
Total new and relapse 9 628    
Previously treated, excluding relapses 65    
Total cases notified 9 693    
Among 9 628 new and relapse cases:
1 022 (11%) cases aged under 15 years; male:female ratio: 1.0
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 996 (34%) 62 (24%) 1 058
Laboratory-confirmed RR-/MDR-TB cases     53
Patients started on MDR-TB treatment ***     50
TB/HIV 2014 Number (%)
TB patients with known HIV status 1 133 (12)
HIV-positive TB patients 22 (2)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0 (0)
HIV-positive TB patients on antiretroviral therapy (ART) 0 (0)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (90) 10 325
Previously treated cases, excluding relapse, registered in 2013 (62) 42
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012    
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Smear (per 100 000 population) 0.9
Culture (per 5 million population) 0.8
Drug susceptibility testing (per 5 million population) 0.8
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? No
Financing TB control 2015  
National TB programme budget (US$ millions) 4.6
% Funded domestically 20%
% Funded internationally 57%
% Unfunded 24%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-04-29 Data: www.who.int/tb/data